Previous close | N/A |
Open | N/A |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | N/A - N/A |
52-week range | 222.00 - 222.00 |
Volume | |
Avg. volume | 0 |
Market cap | 40.081B |
Beta (5Y monthly) | -0.01 |
PE ratio (TTM) | 24.54 |
EPS (TTM) | 9.45 |
Earnings date | 23 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders. “As we reflect on the past year and set our sights on the path ahead, I am truly inspired by the prog
Biogen ( NASDAQ:BIIB ) First Quarter 2024 Results Key Financial Results Revenue: US$2.29b (down 7.0% from 1Q 2023). Net...
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...